Investment Rating - The report maintains an "Outperform the Market" rating for the company [4][20][6] Core Views - The company's first-quarter net profit reached a historical high, with a revenue of 5.44 billion yuan, representing a year-on-year growth of 20.91% and a net profit of 1.88 billion yuan, up 116.18% year-on-year [1][9] - The profitability is supported by a decrease in expense ratios and a sustained high level of R&D investment, with a gross margin of 46.70% and a net margin of 34.70% in the first quarter [1][9] - The methionine market is experiencing price increases, with the average price in 2024 rising by 14.01% compared to 2023, positively impacting the company's performance [2][11] - The company is expanding its production capacity, with a total methionine capacity expected to reach 460,000 tons per year, positioning it as the third-largest globally [2][16] Financial Performance - The company achieved a net profit of 1.88 billion yuan in Q1 2025, with a year-on-year growth of 116.18% and a slight quarter-on-quarter increase of 0.05% [1][9] - The R&D expense ratio was 4.72%, indicating a commitment to innovation and development [1][9] - The forecasted net profits for 2025-2027 are 6.49 billion, 7.09 billion, and 7.62 billion yuan respectively, with corresponding earnings per share of 2.11, 2.31, and 2.48 yuan [4][20] Market Trends - The prices of vitamins A and E are under pressure, while vitamin D3 prices are on the rise, contributing to the overall performance of the company [3][18] - The methionine market is expected to continue benefiting from rising prices and increased production capacity, supporting the company's growth trajectory [2][16]

Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The company reported a significant increase in net profit for Q1 2025, driven by the high demand for refrigerants, with a year-on-year growth of 161% [1] - The refrigerant market is expected to remain strong, supported by demand from downstream sectors such as air conditioning and automotive [4] - The company is projected to achieve net profits of 41 billion, 53 billion, and 61 billion RMB for the years 2025 to 2027, respectively, indicating a robust growth trajectory [5] Revenue and Profitability - In Q1 2025, the company achieved total revenue of 5.8 billion RMB, a year-on-year increase of 6% [1] - The company's gross profit margin improved to 28.4%, reflecting a year-on-year increase of 13.7 percentage points [3] - The earnings per share (EPS) for 2025 is estimated at 1.52 RMB, with a projected growth in EPS for the following years [5] Market Performance - The average price of refrigerants has increased, with R22, R32, R125, and R134a prices rising by 9%, 13%, 7%, and 11% respectively since the beginning of the year [4] - The company's market capitalization is approximately 68.47 billion RMB, with a target price set at 31.92 RMB [9] Segment Performance - The refrigerant segment saw a year-on-year sales increase of 4%, despite a seasonal decline in Q1 [2] - The fluoropolymer segment faced temporary pressure, with a year-on-year sales decline of 7% [2] - The basic chemical products segment benefited from improved caustic soda prices, leading to a revenue increase of 7% year-on-year [3]

基础化工/化学原料 振华股份（603067.SH） Q1 业绩同比高增，关注铬盐产业链景气度整体提升 2025 年 04 月 28 日 投资评级：买入（维持） | 日期 | 2025/4/25 | | --- | --- | | 当前股价(元) | 22.61 | | 一年最高最低(元) | 22.71/9.98 | | 总市值(亿元) | 115.09 | | 流通市值(亿元) | 115.09 | | 总股本(亿股) | 5.09 | | 流通股本(亿股) | 5.09 | | 近 3 个月换手率(%) | 195.81 | 股价走势图 数据来源：聚源 -40% 0% 40% 80% 120% 160% 2024-04 2024-08 2024-12 振华股份 沪深300 相关研究报告 《Q3 业绩环比小幅承压，看好铬盐市 占率持续提升—公司信息更新报告》 -2024.10.30 《Q2 业绩环比大幅增长，关注铬盐与 VK3 持续涨价—公司信息更新报告》 -2024.8.14 金益腾（分析师） 蒋跨跃（分析师） jinyiteng@kysec.cn 证书编号：S0790520020002 jiangkua ...

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]

2025 年 04 月 28 日 公司研究 评级：买入(首次覆盖) 研究所： 证券分析师： 李永磊 S0350521080004 liyl03@ghzq.com.cn 证券分析师： 董伯骏 S0350521080009 dongbj@ghzq.com.cn 证券分析师： 陈云 S0350524070001 cheny17@ghzq.com.cn [Table_Title] 一季度业绩同比大幅提升，矿建加速推进 ——亚钾国际（000893）2024 年年报及 2025 年一季报点评 最近一年走势 | 相对沪深 300 | 表现 | | 2025/04/25 | | --- | --- | --- | --- | | 表现 | 1M | 3M | 12M | | 亚钾国际 | 14.3% | 51.4% | 56.6% | | 沪深 300 | -3.7% | -1.2% | 7.3% | | 市场数据 | | | 2025/04/25 | | 当前价格（元） | | | 29.22 | | 周价格区间（元） 52 | | | 13.65-29.30 | | 总市值（百万） | | | 27,000.78 | | ...

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of 11.88 RMB [6][7]. Core Views - The company's Q1 net profit improved year-on-year, primarily due to the realization of revenue from its real estate business, which is entering a monetization phase [1]. - The dye and intermediate product markets are showing signs of recovery, contributing positively to the company's performance [2]. - The real estate business is expected to continue generating revenue, with a significant inventory of 291.8 billion RMB as of Q1 [3]. - The company has a strong competitive position in the dye industry, which supports its valuation [4]. Summary by Sections Financial Performance - In Q1, the company achieved an operating income of 3.24 billion RMB, with a year-on-year decline of 7.2% and a quarter-on-quarter decline of 38.7%. The net profit attributable to the parent company was 400 million RMB, exceeding expectations [1]. - The sales volume for dyes, additives, and intermediates in Q1 was 56,000 tons, 15,000 tons, and 27,000 tons respectively, with year-on-year growth of 0.8%, 0.3%, and 7.8% [2]. Real Estate Business - The real estate segment is entering a monetization phase, with the "Bay Up" project achieving over 90% sales rate. The inventory as of Q1 increased by 350 million RMB year-on-year [3]. - Non-recurring gains increased by 180 million RMB to 100 million RMB in Q1, mainly due to fair value changes in financial assets and liabilities [3]. Profit Forecast and Valuation - The forecast for net profit attributable to the parent company for 2025-2027 is 2.15 billion RMB, 2.36 billion RMB, and 2.47 billion RMB, respectively, with corresponding EPS of 0.66 RMB, 0.72 RMB, and 0.76 RMB [4]. - The target price is set at 11.88 RMB, based on a 18x PE ratio for 2025, reflecting the company's leading position in the dye industry and orderly progress in real estate projects [4].

2025 年 4 月 27 日 公司研究 维生素量价齐升，业绩持续高增长 ——浙江医药（600216.SH）2024 年年报&2025 年一季报点评 买入（维持） 当前价：13.66 元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：蔡嘉豪 执业证书编号：S0930523070003 021-52523800 caijiahao@ebscn.com 市场数据 | 总股本(亿股) | 9.62 | | --- | --- | | 总市值(亿元)： | 131.36 | | 一年最低/最高(元)： | 9.16/19.40 | | 近 3 月换手率： | 117.62% | 股价相对走势 -10% 19% 49% 78% 108% 04/24 07/24 10/24 01/25 浙江医药 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | 4.19 | -8.57 | 39.64 | | 绝对 | 0.81 | -9.36 | 4 ...

文 ｜ 王喆 2 0 2 5年4月1 8日，振华股份宣布其金属铬产品单吨售价大幅调涨5 0 0 0元，此前公司已于2月1 0日、 3月1 3日连续调涨金属铬单吨售价3 0 0 0 / 2 0 0 0元，2 0 2 5年以来公司金属铬产品单吨售价已累计调涨 1 0 0 0 0元。根据百川盈孚，截至4月2 1日，国内金属铬现货市场均价为6 9 0 0 0元/吨，较2 0 2 5年初上 涨7 5 0 0元/吨。我们看好供需共同催化下金属铬景气度向上超预期，产品价格有望持续上涨，强烈 推荐铬系产品一体化布局龙头公司。 ▍ 战略金属应用价值逐步验证，金属铬国内外需求高增。 金属铬作为地球已知最硬金属，耐高温抗腐蚀属性突出，随着高端需求场景逐步拓展，金属铬战 略价值逐步凸显。目前金属铬价格处历史低位，2 0 2 5年以来金属铬市场均价已连续上涨超1 0%， 我们看好供需共同催化下金属铬景气度向上超预期，产品价格有望持续上涨，强烈推荐铬系产品 一体化布局龙头公司。 本文节选自中信证券研究部已于 2025年4月22日 发布的《 能源化工铬化工行业跟踪点评—金属铬价格跳涨，强烈推荐板块投资机遇 》报告， 具体分析内容（包括相关 ...

文 ｜ 王喆 2 0 2 5年4月1 8日，振华股份宣布其金属铬产品单吨售价大幅调涨5 0 0 0元，此前公司已于2月1 0日、3月1 3日连续调涨金属铬单吨 售价3 0 0 0 / 2 0 0 0元，2 0 2 5年以来公司金属铬产品单吨售价已累计调涨1 0 0 0 0元。根据百川盈孚，截至4月2 1日，国内金属铬现货 市场均价为6 9 0 0 0元/吨，较2 0 2 5年初上涨7 5 0 0元/吨。我们看好供需共同催化下金属铬景气度向上超预期，产品价格有望持续 上涨，强烈推荐铬系产品一体化布局龙头公司。 4月1 8日，振华股份宣布其金属铬产品单吨售价大幅调涨5 0 0 0元，此前公司已于2月1 0日、3月1 3日连续调涨金属铬单吨售价 3 0 0 0 / 2 0 0 0元，2 0 2 5年以来公司金属铬产品单吨售价已累计调涨1 0 0 0 0元。根据百川盈孚，截至4月2 1日，国内金属铬现货市 场均价为6 9 0 0 0元/吨，较2 0 2 5年初上涨7 5 0 0元/吨。根据海关总署统计数据，2 0 1 7年以来中国金属铬出口价格（可理解为不 含税价）在4 4 5 7 3~9 7 9 2 7元/吨波动， ...